In vitro effects of MYCN sense and antisense expression in MYCN-amplified human neuroblastoma cells

被引：0
|
作者：
Kavallaris, M [1 ]
Gardaneh, M [1 ]
Cheung, B [1 ]
Camacho, ML [1 ]
Hocker, JE [1 ]
Norris, MD [1 ]
Haber, M [1 ]
Marshall, GM [1 ]
机构：
[1] Sydney Childrens Hosp, Childrens Canc Res Inst, Randwick, NSW 2031, Australia
来源：
ANTICANCER RESEARCH | 1998年 / 18卷 / 3A期
关键词：
MYCN; neuroblastoma; antisense RNA;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Amplification of the MYCN oncogene is a strong predictor of treatment failure and chemo-resistance in childhood neuroblastoma. Stable expression of two partial MYCN gene fragments in antisense orientation reduced Mycn protein expression in an MYCN-amplified neuroblastoma tumor cell line, however; antisense cells did not exhibit an increased in vitro sensitivity to cytotoxic ol differentiating agents. In contrast, partial MYCN sense transfectants exhibited increased resistance to cytotoxic drugs. These data suggest that the chemo-resistance of MYCN-amplified neuroblastoma cells is complex, and may be due to factors additional to Mycn protein expression.
引用
收藏
页码：1793 / 1797
页数：5
相关论文
共 50 条
  • [21] Management of Stage 4S Composite Neuroblastoma With a MYCN-amplified Nodule
    Bishop, Michael W.
    Yin, Hong
    Shimada, Hiroyuki
    Towbin, Alexander J.
    Miethke, Alexander
    Weiss, Brian
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2014, 36 (01) : E31 - E35
  • [22] Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy
    Valind, Anders
    Verhoeven, Bronte Manouk
    Enoksson, Jens
    Karlsson, Jenny
    Christensson, Gustav
    Manas, Adriana
    Aaltonen, Kristina
    Jansson, Caroline
    Bexell, Daniel
    Baryawno, Ninib
    Gisselsson, David
    Hagerling, Catharina
    ONCOIMMUNOLOGY, 2023, 12 (01):
  • [23] The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma
    Bogen, Dominik
    Brunner, Clemens
    Walder, Diana
    Ziegler, Andrea
    Abbasi, Reza
    Ladenstein, Ruth L.
    Noguera, Rosa
    Martinsson, Tommy
    Amann, Gabriele
    Schilling, Freimut H.
    Ussowicz, Marek
    Benesch, Martin
    Ambros, Peter F.
    Ambros, Inge M.
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (01) : 153 - 163
  • [24] MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling
    Dzieran, Johanna
    Garcia, Aida Rodriguez
    Westermark, Ulrica Kristina
    Henley, Aine Brigette
    Sanchez, Elena Eyre
    Trager, Catarina
    Johansson, Henrik Johan
    Lehtio, Janne
    Arsenian-Henriksson, Marie
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (06) : E1229 - E1238
  • [25] Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma
    Dalton, Krista M.
    Lochmann, Timothy L.
    Floros, Konstantinos, V
    Calbert, Marissa L.
    Kurupi, Richard
    Stein, Giovanna T.
    McClanaghan, Joseph
    Murchie, Ellen
    Egan, Regina K.
    Greninger, Patricia
    Dozmorov, Mikhail
    Ramamoorthy, Sivapriya
    Puchalapalli, Madhavi
    Hu, Bin
    Shock, Lisa
    Koblinski, Jennifer
    Glod, John
    Boikos, Sosipatros A.
    Benes, Cyril H.
    Faber, Anthony C.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (13)
  • [26] The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells
    O'Brien, Eleanor M.
    Selfe, Joanna L.
    Martins, Ana Sofia
    Walters, Zoe S.
    Shipley, Janet M.
    BMC CANCER, 2018, 18
  • [27] Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma
    Schramm, Alexander
    Koester, Johannes
    Marschall, Tobias
    Martin, Marcel
    Schwermer, Melanie
    Fielitz, Kathrin
    Buechel, Gabriele
    Barann, Matthias
    Esser, Daniela
    Rosenstiel, Philip
    Rahmann, Sven
    Eggert, Angelika
    Schulte, Johannes H.
    INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (03) : E106 - E115
  • [28] Reversing the HDAC-inhibitor mediated metabolic escape in MYCN-amplified neuroblastoma
    Bishayee, Kausik
    Nazim, Uddin Md.
    Kumar, Vijay
    Kang, Jieun
    Kim, Jaebong
    Huh, Sung-Oh
    Sadra, Ali
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 150
  • [29] Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration
    Zaatiti, Hayat
    Abdallah, Jad
    Nasr, Zeina
    Khazen, George
    Sandler, Anthony
    Abou-Antoun, Tamara J.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 52 (03) : 787 - 803
  • [30] Multi-omic profiling of MYCN-amplified neuroblastoma cell-lines
    Dassi, Erik
    Greco, Valentina
    Sidarovich, Viktoryia
    Zuccotti, Paola
    Arseni, Natalia
    Scaruffi, Paola
    Tonini, Gian Paolo
    Quattrone, Alessandro
    GENOMICS DATA, 2015, 6 : 285 - 287
12345